Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies Pharmaceutical Investing
Bristol Myers Squibb to Present at J.P. Morgan's 41st Annual Healthcare Conference Pharmaceutical Investing
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York Pharmaceutical Investing
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics Pharmaceutical Investing
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma Pharmaceutical Investing
Sunlenca® Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV Pharmaceutical Investing
Gilead Sciences: Tatiana Williams Leads the Way With the Transinclusive Group Pharmaceutical Investing
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer Pharmaceutical Investing
